PYXS
PYXS
NASDAQ · Biotechnology

Pyxis Oncology Inc

$1.64
+0.01 (+0.61%)
Financial Highlights (FY 2026)
Revenue
24.46M
Net Income
-140,524,510
Gross Margin
82.8%
Profit Margin
-574.6%
Rev Growth
—
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 82.8% 50.2% 50.2% 50.2%
Operating Margin -609.2% -29.7% -26.7% -27.8%
Profit Margin -574.6% -29.2% -26.4% -22.9%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 24.46M 59.72M 61.79M 57.95M
Gross Profit 20.24M 29.95M 30.99M 29.07M
Operating Income -148,988,157 -17,718,696 -16,524,048 -16,125,975
Net Income -140,524,510 -17,457,928 -16,293,891 -13,275,510
Gross Margin 82.8% 50.2% 50.2% 50.2%
Operating Margin -609.2% -29.7% -26.7% -27.8%
Profit Margin -574.6% -29.2% -26.4% -22.9%
Rev Growth — -4.4% +5.4% +21.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 39.7K 9.30M 10.88M 8.95M
Total Equity 99.21M 30.51M 34.64M 32.57M
D/E Ratio 0.00 0.30 0.31 0.27
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -145,284,335 -19,228,267 -21,164,861 -19,065,899
Free Cash Flow — -18,637,383 -17,592,445 -15,576,212